Prime Medicine, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Prime Medicine, Inc. (PRME) reported Net Income (Loss) Available to Common Stockholders, Basic of -$42.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- Prime Medicine, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$42.11M.
- Prime Medicine, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$49.12M.
- Prime Medicine, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$46.08M.
- Prime Medicine, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$50.58M.
- Prime Medicine, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$201.14M.
- Prime Medicine, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$195.88M.
- Prime Medicine, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$198.13M.
- Prime Medicine, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$142.01M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.11M 10-Q · filed 2026-08-06 | -$91.23M 10-Q · filed 2026-08-06 | -$137.31M derived: sum of 3 quarters · filed 2026-08-06 | -$187.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$49.12M 10-Q · filed 2026-05-07 | -$95.20M derived: sum of 2 quarters · filed 2026-05-07 | -$145.78M derived: sum of 3 quarters · filed 2026-05-07 | -$198.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$46.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$96.66M derived: sum of 2 quarters · filed 2026-03-03 | -$149.25M derived: sum of 3 quarters · filed 2026-08-06 | -$201.14M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$50.58M 10-Q · filed 2025-11-07 | -$103.17M derived: sum of 2 quarters · filed 2026-08-06 | -$155.06M 10-Q · filed 2025-11-07 | -$197.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$52.59M 10-Q · filed 2026-08-06 | -$104.48M 10-Q · filed 2026-08-06 | -$146.76M derived: sum of 3 quarters · filed 2026-08-06 | -$199.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$51.89M 10-Q · filed 2026-05-07 | -$94.17M derived: sum of 2 quarters · filed 2026-05-07 | -$146.68M derived: sum of 3 quarters · filed 2026-05-07 | -$202.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$42.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$94.79M derived: sum of 2 quarters · filed 2026-03-03 | -$150.12M derived: sum of 3 quarters · filed 2026-03-03 | -$195.88M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$52.52M 10-Q · filed 2025-11-07 | -$107.84M derived: sum of 2 quarters · filed 2025-11-07 | -$153.61M 10-Q · filed 2025-11-07 | -$219.25M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$55.33M 10-Q · filed 2025-08-07 | -$101.09M 10-Q · filed 2025-08-07 | -$166.73M derived: sum of 3 quarters · filed 2025-08-07 | -$217.44M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$45.76M 10-Q · filed 2025-05-08 | -$111.40M derived: sum of 2 quarters · filed 2025-05-08 | -$162.11M derived: sum of 3 quarters · filed 2025-05-08 | -$204.50M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$65.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$116.35M derived: sum of 2 quarters · filed 2025-02-28 | -$158.74M derived: sum of 3 quarters · filed 2025-02-28 | -$198.13M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$50.71M 10-Q · filed 2024-11-12 | -$93.09M derived: sum of 2 quarters · filed 2024-11-12 | -$132.49M 10-Q · filed 2024-11-12 | -$173.09M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$42.38M 10-Q · filed 2024-08-08 | -$81.78M 10-Q · filed 2024-08-08 | -$122.38M derived: sum of 3 quarters · filed 2024-08-08 | -$158.09M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$39.40M 10-Q · filed 2024-05-10 | -$79.99M derived: sum of 2 quarters · filed 2024-05-10 | -$115.71M derived: sum of 3 quarters · filed 2024-05-10 | -$151.35M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$40.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$76.31M derived: sum of 2 quarters · filed 2024-03-01 | -$111.95M derived: sum of 3 quarters · filed 2024-03-01 | -$142.01M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$35.71M 10-Q · filed 2023-11-03 | -$71.35M derived: sum of 2 quarters · filed 2023-11-03 | -$101.42M 10-Q · filed 2023-11-03 | -$170.69M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$35.64M 10-Q · filed 2023-08-07 | -$65.70M 10-Q · filed 2023-08-07 | -$134.98M derived: sum of 3 quarters · filed 2023-08-07 | -$157.75M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$30.06M 10-Q · filed 2023-05-11 | -$99.34M derived: sum of 2 quarters · filed 2023-05-11 | -$122.11M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$69.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$92.05M derived: sum of 2 quarters · filed 2023-03-09 | -$184.12M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$22.77M 10-Q · filed 2022-11-14 | -$114.85M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | -$5.05M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |